Synovio-entheseal inflammation and the tipping point from PsO to PsA Save

Psoriatic arthritis develops in approximately 20 to 30 per cent of patients with psoriasis, yet predicting which patients will make the transition and when, has remained one of the most clinically challenging questions in rheumatology. The consequences of a missed diagnosis are substantial. Joint damage begins early in PsA, and by the time arthritis is clinically evident, subclinical inflammatory processes have frequently been underway for months. The EULAR definition of subclinical PsA is psoriasis associated with recent-onset arthralgia and imaging abnormalities, in the absence of clinically evident arthritis. This provides a conceptual framework, but translating that framework into actionable clinical differentiation has until now been difficult.

A study presented at EULAR 2026 (Abstract OP0183) provides the most granular ultrasound characterisation yet of the journey from psoriasis, through subclinical disease, to early clinical PsA. The study identifies the specific imaging features that distinguish patients whose arthralgia is progressing toward arthritis from those who remain stable.

The study enrolled 183 patients from prospective observational cohorts and classified them into four groups based on their clinical and longitudinal status: patients with psoriasis but no musculoskeletal symptoms who did not develop PsA during follow-up (PsO); patients with stable subclinical PsA with psoriasis plus arthralgia who did not progress to clinical arthritis (s-scPsA); patients with progressing subclinical PsA with arthralgia that subsequently evolved into clinically manifest arthritis (p-scPsA); and patients with newly diagnosed early PsA. All patients underwent blinded clinical assessment and comprehensive musculoskeletal ultrasound scanning of 42 regions including joints, entheses, tendons, and bursae at baseline. The study was cross-sectional, with subclinical classification assigned retrospectively based on longitudinal outcome.

The most striking finding is what did not differentiate patients who progressed from those who remained stable. Tender joint count, BASDAI, VAS pain, and HAQ showed substantial overlap between stable and progressing subclinical PsA groups and were not significantly associated with subsequent progression in univariate analyses. This is a critical clinical message: patients who are heading toward clinical arthritis do not look clinically different from those who are not. Standard patient-reported outcomes and physical examination are insufficient to identify who is at risk.

Ultrasound, however, did differentiate the groups. 

Compared with patients with stable subclinical PsA, those who subsequently progressed to clinical arthritis had significantly higher rates of ultrasound-detected active synovitis (odds ratio 3.40, p = 0.019) and active enthesitis (OR 3.45, p = 0.049) at baseline before any joint swelling was clinically apparent. The distinction was sharp: ultrasound-defined synovio-entheseal complex (SEC) inflammation is present and elevated in progressors but absent or at psoriasis-only levels in those who remain stable.

As the disease progressed from subclinical to early clinical PsA, the ultrasound signal shifted further. PD-positive tenosynovitis and peritendinitis emerge as distinguishing features of the early clinical stage. They were rare or absent in progressing subclinical PsA but significantly more frequent in established early PsA (p < 0.001 and p = 0.05 respectively). This suggests a sequential inflammatory evolution: first, SEC inflammation (enthesitis and synovitis) activates during subclinical disease, and tenosynovitis then amplifies as clinical arthritis declares.

These findings have immediate implications for the emerging field of PsA interception. This is  the idea that intervening therapeutically before clinical arthritis develops could prevent or delay joint disease. The EULAR 2026 programme included several abstracts specifically addressing PsA interception. The imaging data provided the mechanistic step: ultrasound-detected synovio-entheseal inflammation is the measurable marker of clinical transition, months before swollen joints appear.

The study provides a validated imaging strategy with systematic ultrasound of entheses and synovium for risk-stratifying psoriasis patients with arthralgia. The EULAR definition of subclinical PsA, previously somewhat abstract, now has an imaging correlation with predictive validity.

The limitations are those inherent in the study design: relatively small numbers in the progressing and early PsA groups (n = 23 and n = 25), the cross-sectional analytical approach, and the exploratory nature of the statistical comparisons without adjustment for multiple testing. Prospective studies with larger cohorts, designed to test these ultrasound thresholds as predictive biomarkers, are now the logical next step. This is a proof-of-concept demonstration that imaging can identify the tipping point from psoriasis to arthritis before clinicians can.